🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Muscle Invasive Bladder Urothelial Carcinoma

Chemoablation for Low-Grade Bladder Cancer NCT07019220Phase 21 site📍 Vienna Ekaterina Laukhtina · Tests: Gemcitabine Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial NCT07726602n/a1 site📍 Portland OHSU Knight Cancer Institute · Tests: Non-Interventional Study Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy NCT06170177n/a1 site📍 Milan IRCCS San Raffaele · Tests: Radical Cystectomy Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer NCT05833867Phase 11 site📍 Cleveland Shilpa Gupta, MD · Tests: Sacituzumab govitecan, Adaptive Radiotherapy Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer NCT07067749Phase 31 site📍 Rome University of Rome Tor Vergata · Tests: multiparametric magnetic resonance imaging (mpMRI) of the bladder, Transurethral resection of bladder tumour (TURBt), C… A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer NCT06503614Phase 25 sites📍 San Francisco📍 Tampa📍 New Brunswick John Sfakianos · Tests: Durvalumab, Monalizumab FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 NCT05614739Phase 182 sites📍 Tucson📍 Duarte📍 Los Angeles Eli Lilly and Company · Tests: Vepugratinib, Pembrolizumab, enfortumab vedotin, Trastuzumab Deruxtecan, Midazolam Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS) NCT07855926n/a1 site📍 Munich LMU Klinikum · Tests: Perioperative Systemic Therapy Registry A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer NCT05521698Phase 16 sites📍 Tucson📍 Los Angeles📍 Bethesda University of Wisconsin, Madison · Tests: Bicalutamide, Biopsy Procedure, Biospecimen Collection, Questionnaire Administration, Transurethral Resection of Bladde… Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer NCT06809140Phase 25 sites📍 Duarte📍 Indianapolis📍 New York Matthew Galsky · Tests: Enfortumab vedotin, Pembrolizumab Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC? NCT07625527Phase 24 sites📍 Tianjin📍 Tianjin📍 Tianjin Tianjin Medical University Second Hospital · Tests: Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer NCT07717242Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Disitamab vedotin, Toripalimab, Sitagliptin, Zeprumetostat, Tafolecimab Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations NCT06511648Phase 223 sites📍 Clermont-Ferrand📍 Lyon📍 Paris Spanish Oncology Genito-Urinary Group · Tests: Erdafitinib monotherapy, Cetrelimab and Erdafitinib combination Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors NCT06493552Phase 2, Phase 31 site📍 Santa Monica Vasgene Therapeutics, Inc · Tests: SEphB4-HSA, Pembrolizumab, Gemcitabine, Cisplatin, Enfortumab vedotin EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC NCT07647289Phase 21 site📍 Beijing Peking University Third Hospital · Tests: enfortumab vedotin (EV), Toripalimab, Gemcitabine (Chemotherapy), Cisplatin Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial NCT07061964Phase 2181 sites📍 Birmingham📍 Gilbert📍 Phoenix National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy NCT07225205NA2 sites📍 Baltimore📍 Baltimore Johns Hopkins University · Tests: Intravenous fluids, ERAS Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC NCT07322263Phase 21 site📍 Iowa City Michael A. O'Donnell · Tests: Intravesical Gemcitabine and Docetaxel Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer NCT07480356Phase 311 sites📍 Queen Creek📍 Little Rock📍 Bakersfield Protara Therapeutics · Tests: TARA-002, Investigator's Choice of Intravesical Chemotherapy Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma NCT06257017Phase 21 site📍 Hong Kong Yung NA · Tests: gemcitabine, Cisplatin Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment NCT06766266Phase 11 site📍 Chongqing First Affiliated Hospital of Chongqing Medical University · Tests: Irinotecan liposome II combination therapy regimen, Irinotecan liposome II combination therapy regimen Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study NCT05987241Phase 2, Phase 3504 sites📍 Phoenix📍 Phoenix📍 Tucson National Cancer Institute (NCI) · Tests: Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy NCT07234968NA2 sites📍 Philadelphia📍 Philadelphia Thomas Jefferson University · Tests: Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) NCT05037279Phase 36 sites📍 Vancouver📍 Kingston📍 Toronto Verity Pharmaceuticals Inc. · Tests: Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus Calmette-Guerin: Strain TICE Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE) NCT06396533n/a2 sites📍 Omaha📍 Philadelphia Fox Chase Cancer Center A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors NCT05706129Phase 1, Phase 210 sites📍 Melbourne📍 Sydney📍 Clermont-Ferrand Lumara Bio Oncologics GmbH · Tests: [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452 Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) NCT07566156Phase 326 sites📍 Little Rock📍 Santa Barbara📍 Aurora Astellas Pharma Global Development, Inc. · Tests: Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy, Cisplatin, Fluorouracil Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging NCT07602010n/a1 site📍 Oslo Oslo University Hospital Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study NCT07097142Phase 3259 sites📍 Fairbanks📍 Fort Smith📍 Little Rock NRG Oncology · Tests: Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC NCT07725796Phase 115 sites📍 Queen Creek📍 Bakersfield📍 Murrieta UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. · Tests: UGN-501
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy